2024 wasn’t a breakout year for #biopharma, but signs of recovery emerged. #VC funding surged to post-2021 highs, M&A stayed cautious, and IPOs made a slow return. Read the full report from Evaluate here: ow.ly/vVyO50VJW7c

Clora client PathosAI is teaming up with AstraZeneca & Tempus to build a multimodal #AI model for #oncology R&D—leveraging Tempus' vast clinical data. A major step for AI in #precisionmedicine. Read more: ow.ly/2tMh50VMWob

CROs like Icon & Medpace report a surge in delayed or canceled R&D projects, driven by federal funding cuts and #tariff uncertainty. These disruptions pose serious challenges for #lifesciences firms relying on steady development timelines. Read more here: ow.ly/rHTp50VQaUQ

.Eli Lilly and Company CEO Dave Ricks urges the U.S. to end “tit-for-tat” #tariffs, warning they backfire on U.S. industries. He calls for #tradedeals that level the playing field & drive innovation instead. Read more: ow.ly/FtvL50VU5FI #pharma #tradepolicy #biotech

Big #pharma is pushing ahead with M&A despite looming #tariffs. Companies like Merck say #businessdevelopment is still top priority—even as trade policies raise costs. Activity is heating up as the industry braces for impact. ow.ly/zJv750VWFwu

Hear Rahul Chaturvedi talk with RTW Investments, LP's Stephanie Sirota about her path from journalism to #biotech #investing, growing RTW into a global leader, and what’s next for GLP-1s, biotech financing, and U.S. #healthcare. Listen now!

Clora client Spero Therapeutics, in collaboration with GSK, reports positive Ph3 results for tebipenem HBr in cUTIs. It could become the first oral carbapenem for U.S. patients—an IV-free breakthrough in treatment. We're proud to support their journey. Read more: ow.ly/PjWI50W1MGK

Shrinking budgets. Hiring freezes. Overloaded teams. In #biotech and #pharma, the pressure is mounting—leading to burnout, missed milestones, and delays. See how leaders are maintaining progress without growing headcount: ow.ly/2fkx50W3is2

.Evaluate's 2025 World Preview report shows steady #pharma growth despite market turbulence. #Oncology remains strong and #neurology is gaining momentum. Big M&A deals highlight interest, though overall activity is slowing amid policy uncertainty: ow.ly/H6Kx50Wjbes

The FDA has removed REMS requirements for all approved autologous CAR-T therapies, improving access to #celltherapies for #bloodcancers, especially in rural areas, while maintaining safety standards. Read the full update here: ow.ly/V5yU50Wjbwa

New Biotech2050 Podcast episode: Rahul Chaturvedi talks with REGENXBIO CEO Curran Simpson about his path from engineer to #biotech leader, tackling #rarediseases, and the promise of one-time #genetherapies. Listen now.

Clora client Rhythm reported strong Ph2 results for its oral #obesity therapy, showing up to 9.3% BMI reduction in 14 weeks. Safe, effective, and pill-based—this could be a game changer. Read more here: ow.ly/CxpG50WweGN

Clora CEO Rahul Chaturvedi talks with Jeremy Bender of Day One Biopharmaceuticals about transforming pediatric #oncology, securing #FDA approval, building culture, and using #AI in trials. A candid look at #leadership, focus, and innovation in #biotech. Listen now.

In #biotech and #pharma, timeline delays don’t just slow progress, they jeopardize funding. With hiring lagging, how can teams keep up? See how companies can access expert help fast to stay on track: ow.ly/nC3f50W3iHh

Clora is proud to sponsor this episode of Biotech2050 Podcast. Hear Rahul Chaturvedi talk with Amirali Talasaz of Guardant Health about scaling #liquidbiopsy tech, raising $3B+, and building patient-first innovation. Listen to the #podcast using the link below.

.Ossium Health CEO Kevin Caldwell joins Clora CEO Rahul Chaturvedi on Biotech2050 Podcast to discuss building the first scalable bone marrow bank and redefining #celltherapy. Hear about his bold vision for #healthspan and #immunehealth. Listen to the new #podcast episode now.

Congratulations to Clora client Circle Pharma on their partnership with Eli Lilly and Company to accelerate oral macrocycle drug development. Read more in their press release: ow.ly/x6Ep50WXBu5 #biotech #drugdiscovery #lifesciences #pharma

Clora CEO Rahul Chaturvedi joins Geoffrey Duyk, CEO of Grove Biopharma, to talk #biotech headwinds, R&D inefficiencies, and synthetic protein mimetics tackling “undruggable” targets. Don’t miss this Biotech2050 Podcast episode. Listen now using the link below.

Clora is heading to JPM 2026! Our CEO Rahul Chaturvedi will be in SF and open to meetings. Let’s talk about solving talent gaps with fractional expertise and accelerating development without traditional hiring costs. Send us a message to request a meeting. #JPM2026 #Clora #LifeSciences

🎙️ Jim Tananbaum, CEO of Foresite Capital, joins Clora CEO Rahul Chaturvedi to explore #biotech innovation, #AI in #drugdiscovery, and investing through market cycles. A must-listen on strategy, #science, and impact. Listen using the link below.